<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03201562</url>
  </required_header>
  <id_info>
    <org_study_id>PRX100.FDAIIb</org_study_id>
    <nct_id>NCT03201562</nct_id>
  </id_info>
  <brief_title>A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia</brief_title>
  <official_title>A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Presbyopia Therapies, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Presbyopia Therapies, LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of PRX-100 compared with aceclidine alone and vehicle in&#xD;
      the treatment of early to moderate presbyopia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 30, 2017</start_date>
  <completion_date type="Actual">May 20, 2018</completion_date>
  <primary_completion_date type="Actual">May 20, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects With at Least a 3 Line (15 Letter) Improvement in Near Visual Acuity in the Study Eye</measure>
    <time_frame>1 hour post-treatment</time_frame>
    <description>Proportion of subjects with at least a 3 line (15 letter) improvement in near visual acuity in the study eye at 1 hour post-treatment in the mITT population</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>Aceclidine+tropicamide combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aceclidine+tropicamide combination single dose (PRX-100 Ophthalmic Solution)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aceclidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aceclidine single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Vehicle single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aceclidine+tropicamide combination</intervention_name>
    <description>Ophthalmic Solution</description>
    <arm_group_label>Aceclidine+tropicamide combination</arm_group_label>
    <other_name>PRX-100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aceclidine</intervention_name>
    <description>Ophthalmic Solution</description>
    <arm_group_label>Aceclidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Ophthalmic Solution</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be able and willing to provide written informed consent and sign Health Information&#xD;
             Portability and Accountability Act (HIPAA) form prior to any study procedure being&#xD;
             performed;&#xD;
&#xD;
          2. Be able and willing to follow all instructions and attend study visits;&#xD;
&#xD;
          3. Be 48-64 years of age of either sex and any race or ethnicity at visit 1;&#xD;
&#xD;
          4. Be an early to moderate presbyope determined by screening monocular best-corrected&#xD;
             distance visual acuity (VA) at 45 cm&#xD;
&#xD;
          5. Be able and willing to avoid all disallowed medications for the appropriate washout&#xD;
             period and during the study without significant risk to the subject.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Be a female of childbearing potential who is currently pregnant, nursing or planning a&#xD;
             pregnancy;&#xD;
&#xD;
          2. Have known contraindications or sensitivity to the use of any of the study&#xD;
             medications(s) or their components;&#xD;
&#xD;
          3. Have an active ocular infection at visit 1 (bacterial, viral or fungal), positive&#xD;
             history of an ocular herpetic infection, preauricular lymphadenopathy, or ongoing,&#xD;
             active ocular inflammation (eg, moderate to severe blepharitis, allergic&#xD;
             conjunctivitis, peripheral ulcerative keratitis, scleritis, uveitis) in either eye;&#xD;
&#xD;
          4. Have moderate or severe dry eye;&#xD;
&#xD;
          5. Have clinically significant abnormal lens findings (eg cataract) including early lens&#xD;
             changes and/or any evidence of a media opacity in either eye;&#xD;
&#xD;
          6. Have dark-adapted pupillometry measurements of &lt; 4.0 mm in either eye;&#xD;
&#xD;
          7. Have intraocular pressure (IOP) that is less than 5 millimeters of mercury (mmHg) or&#xD;
             greater than 22 mmHg in either eye documented at visit 1, or have a prior diagnosis of&#xD;
             ocular hypertension or glaucoma or currently being treated with any type of topical&#xD;
             IOP lowering (glaucoma) medication at visit 1;&#xD;
&#xD;
          8. Have abnormal findings on dilated fundus exam in either eye documented within 3 months&#xD;
             of visit 1 or a known history of retinal detachment or clinically significant retinal&#xD;
             disease in either eye;&#xD;
&#xD;
          9. Have a known history or diagnosis in the past of: iritis, scleritis or uveitis,&#xD;
             whether active or inactive;&#xD;
&#xD;
         10. Have had surgical intervention (ocular or systemic) within 6 months prior to visit 1,&#xD;
             or planned surgical intervention within 30 days after visit 4;&#xD;
&#xD;
         11. Have undergone refractive eye surgery (incisional keratotomy, photorefractive&#xD;
             keratectomy [PRK], laser in situ keratomileusis [LASIK], laser-assisted sub-epithelial&#xD;
             keratectomy [LASEK]), corneal inlay procedures, cataract extraction, or intraocular&#xD;
             lens placement;&#xD;
&#xD;
         12. Use artificial tears or lubricant eye ointment on a daily basis;&#xD;
&#xD;
         13. Have an inability or refuse to discontinue soft contact lens wear 7 days prior to&#xD;
             study visit 1 and rigid gas permeable (RGP) contact lens wear 14 days prior to visit 1&#xD;
             and during the study;&#xD;
&#xD;
         14. Use any of the following disallowed medications during the 2 weeks (14 days) prior to&#xD;
             visit 1 and during the study:&#xD;
&#xD;
               1. narcotic (opiate class) pain medication (eg, codeine, OxyContin®, Vicodin®,&#xD;
                  Tramadol®)&#xD;
&#xD;
               2. bladder medication (eg Urecholine®, bethanechol)&#xD;
&#xD;
               3. antipsychotics&#xD;
&#xD;
               4. antidepressants&#xD;
&#xD;
               5. attention -deficit/hyperactivity disorder (ADHD) medications&#xD;
&#xD;
               6. alpha-blockers (eg, tamsulosin, Flomax®, Jayln®, Uroxatral®, Rapaflo®)&#xD;
&#xD;
               7. anticholinergics (eg, atropine, belladonna, benztropine, dicyclomine, donepezil,&#xD;
                  hyoscyamine, propantheline, scopolamine, trihexphenidyl)&#xD;
&#xD;
               8. muscarinic receptor agonists or cholinergic agonists (eg, Salagen®, Evoxac®)&#xD;
&#xD;
               9. over-the-counter (OTC) or prescription antihistamines or decongestants&#xD;
&#xD;
              10. any prescribed topical ophthalmic medications&#xD;
&#xD;
              11. recreational drug use (eg, marijuana, methadone, heroin, cocaine);&#xD;
&#xD;
         15. Have a diagnosis of diabetes mellitus or a history of elevated blood sugar;&#xD;
&#xD;
         16. Have a condition or a situation, which in the Investigator's opinion, may put the&#xD;
             subject at increased risk, confound study data, or interfere significantly with the&#xD;
             subject's study participation, including but not limited to unstable: cardiovascular,&#xD;
             hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic,&#xD;
             hematologic, neurologic, or psychiatric disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>48 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail Torkildsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Andover Eye Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 26, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <results_first_submitted>March 24, 2021</results_first_submitted>
  <results_first_submitted_qc>March 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2021</results_first_posted>
  <disposition_first_submitted>December 4, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>December 4, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 8, 2020</disposition_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tropicamide</mesh_term>
    <mesh_term>Aceclidine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03201562/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03201562/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Crossover Sequence 1</title>
          <description>Aceclidine+tropicamide combination Visit 1, Aceclidine Visit 2, Vehicle Visit 3</description>
        </group>
        <group group_id="P2">
          <title>Crossover Sequence 2</title>
          <description>Aceclidine Visit 1, Vehicle Visit 2, Aceclidine+tropicamide combination Visit 3</description>
        </group>
        <group group_id="P3">
          <title>Crossover Sequence 3</title>
          <description>Vehicle Visit 1, Aceclidine+tropicamide combination Visit 2, Aceclidine Visit 3</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Crossover Sequence 1</title>
          <description>Aceclidine+tropicamide combination Visit 1, Aceclidine Visit 2, Vehicle Visit 3</description>
        </group>
        <group group_id="B2">
          <title>Crossover Sequence 2</title>
          <description>Aceclidine Visit 1, Vehicle Visit 2, Aceclidine+tropicamide combination Visit 3</description>
        </group>
        <group group_id="B3">
          <title>Crossover Sequence 3</title>
          <description>Vehicle Visit 1, Aceclidine+tropicamide combination Visit 2, Aceclidine Visit 3</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.8" spread="3.29"/>
                    <measurement group_id="B2" value="55.7" spread="4.28"/>
                    <measurement group_id="B3" value="56.2" spread="4.51"/>
                    <measurement group_id="B4" value="55.6" spread="4.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects With at Least a 3 Line (15 Letter) Improvement in Near Visual Acuity in the Study Eye</title>
        <description>Proportion of subjects with at least a 3 line (15 letter) improvement in near visual acuity in the study eye at 1 hour post-treatment in the mITT population</description>
        <time_frame>1 hour post-treatment</time_frame>
        <population>The treatment crossover design allowed for each treatment to be analyzed in all 58 subjects. The primary efficacy analysis was performed on a mITT population of subjects meeting the baseline criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Aceclidine+Tropicamide Combination</title>
            <description>Aceclidine+tropicamide combination single dose</description>
          </group>
          <group group_id="O2">
            <title>Aceclidine</title>
            <description>Aceclidine single dose</description>
          </group>
          <group group_id="O3">
            <title>Vehicle</title>
            <description>Vehicle single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With at Least a 3 Line (15 Letter) Improvement in Near Visual Acuity in the Study Eye</title>
          <description>Proportion of subjects with at least a 3 line (15 letter) improvement in near visual acuity in the study eye at 1 hour post-treatment in the mITT population</description>
          <population>The treatment crossover design allowed for each treatment to be analyzed in all 58 subjects. The primary efficacy analysis was performed on a mITT population of subjects meeting the baseline criteria.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.22"/>
                    <measurement group_id="O2" value="47.22"/>
                    <measurement group_id="O3" value="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>Generalized Estimating Equation (GEE)</method>
            <method_desc>GEE model includes 3-line improvement as response variable with sequence, period, treatment as fixed effect, subject within sequence as random effect.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>38.436</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.262</ci_lower_limit>
            <ci_upper_limit>235.936</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>Generalized Estimating Equation (GEE)</method>
            <method_desc>GEE model includes 3-line improvement as response variable with sequence, period, treatment as fixed effect, subject within sequence as random effect.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>36.893</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.936</ci_lower_limit>
            <ci_upper_limit>229.310</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9298</p_value>
            <method>Generalized Estimating Equation (GEE)</method>
            <method_desc>GEE model includes 3-line improvement as response variable with sequence, period, treatment as fixed effect, subject within sequence as random effect</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.042</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.485</ci_lower_limit>
            <ci_upper_limit>2.239</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected for up to 50 days.</time_frame>
      <desc>Safety population includes all randomized subjects who receive at least one dose of the study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Aceclidine+Tropicamide Combination</title>
          <description>Aceclidine+tropicamide combination single dose</description>
        </group>
        <group group_id="E2">
          <title>Aceclidine</title>
          <description>Aceclidine single dose</description>
        </group>
        <group group_id="E3">
          <title>Vehicle</title>
          <description>Vehicle single dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation site pain (mild)</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Instillation site pain (moderate)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI must not present the study results until the aggregate multi-site study results are published. The PI must submit to sponsor any proposed publication or presentation at least 60 days prior to the submission. Sponsor may require the delay of publication or presentation for an additional period of time not to exceed 120 days for the purposes of filing patent applications to patentable subject matter or the resolution of any inaccuracies or misleading statements.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jerry Horn, MD</name_or_title>
      <organization>Presbyopia Therapies, LLC</organization>
      <phone>(847)-772-8885</phone>
      <email>visionxcl@icloud.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

